SHANGHAI , Dec. 9, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round.

The funding round was backed by a distinguished group of investors, including IDG Capital and SongQing Capital. Existing investors — WuXi AppTec's Corporate Venture Fund, Temasek, HSG, MPCi, and Medicxi — also contributed to the round. The robust involvement from both new and current investors highlights widespread confidence in D3 Bio's innovative pipeline and its global development strategy.

Proceeds from this financing will primarily support the planned global Phase III pivotal program for the company's lead asset, elisrasib (D3S-001). These piv

See Full Page